|Bid||1,314.50 x 0|
|Ask||1,315.50 x 0|
|Day's range||1,290.50 - 1,317.49|
|52-week range||1,227.00 - 1,681.50|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||28.60|
|Earnings date||29 Jul 2021|
|Forward dividend & yield||0.27 (2.09%)|
|Ex-dividend date||30 Sept 2021|
|1y target est||16.45|
Smith & Nephew (LON:SN.) has had a rough three months with its share price down 19%. But if you pay close attention...
How far off is Smith & Nephew plc ( LON:SN. ) from its intrinsic value? Using the most recent financial data, we'll...
Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. In February of this year, Bioventus opened its doors of ownership to the public by way of an IPO of 8 million shares. Leading up to the spin-off, Smith & Nephew was experiencing strong growth from the biologics and clinical therapies unit, with annual revenue growing from $52 million in 2004 to $223 million in 2010 for that unit alone.